Validation of a novel composite of skin biomarkers as a primary outcome measure for evaluating the safety of treatments for atopic dermatitis: a randomized controlled trial (phase 2) comparing the effects of crisaborole 2% ointment to betamethasone valerate 0.1% cream on skin structure and function in participants with atopic dermatitis.

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2020
This article has no abstract
Epistemonikos ID: 9a2640f3a22d6f6a4443d4e796feb3f0918ddcad
First added on: Jul 27, 2021